These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31564018)

  • 1. Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care.
    Gulilat M; Keller D; Linton B; Pananos AD; Lizotte D; Dresser GK; Alfonsi J; Tirona RG; Kim RB; Schwarz UI
    J Thromb Thrombolysis; 2020 Feb; 49(2):294-303. PubMed ID: 31564018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation.
    Ueshima S; Hira D; Kimura Y; Fujii R; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Ohno S; Horie M; Terada T; Katsura T
    Br J Clin Pharmacol; 2018 Jun; 84(6):1301-1312. PubMed ID: 29457840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
    Ueshima S; Hira D; Fujii R; Kimura Y; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Horie M; Terada T; Katsura T
    Pharmacogenet Genomics; 2017 Sep; 27(9):329-336. PubMed ID: 28678049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of
    Skripka AI; Krupenin PM; Kozhanova ON; Kudryavtseva AA; Fedina LV; Akmalova KA; Bochkov PO; Sokolova AA; Napalkov DA; Sychev DA
    Drug Metab Pers Ther; 2024 Jun; 39(2):89-97. PubMed ID: 38943286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.
    Nakagawa J; Kinjo T; Iizuka M; Ueno K; Tomita H; Niioka T
    Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):297-304. PubMed ID: 32920985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients.
    Roşian AN; Roşian ŞH; Kiss B; Ştefan MG; Trifa AP; Ober CD; Anchidin O; Buzoianu AD
    Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32316515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impacts of pregnane X receptor and cytochrome P450 oxidoreductase gene polymorphisms on trough concentrations of apixaban in patients with non-valvular atrial fibrillation.
    Nakagawa J; Kinjo T; Aiuchi N; Ueno K; Tomita H; Niioka T
    Eur J Clin Pharmacol; 2023 Jan; 79(1):127-135. PubMed ID: 36399204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
    Otsuka Y; Choules MP; Bonate PL; Komatsu K
    CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban plasma concentrations before and after catheter ablation for atrial fibrillation.
    Aakerøy R; Loennechen JP; Dyrkorn R; Lydersen S; Helland A; Spigset O
    PLoS One; 2024; 19(7):e0308022. PubMed ID: 39083480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
    Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
    Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.
    Skeppholm M; Al-Aieshy F; Berndtsson M; Al-Khalili F; Rönquist-Nii Y; Söderblom L; Östlund AY; Pohanka A; Antovic J; Malmström RE
    Thromb Res; 2015 Jul; 136(1):148-53. PubMed ID: 25981142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial apixaban dosing in patients with atrial fibrillation.
    Buchholz A; Ueberham L; Gorczynska K; Dinov B; Hilbert S; Dagres N; Husser D; Hindricks G; Bollmann A
    Clin Cardiol; 2018 May; 41(5):671-676. PubMed ID: 29542830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose.
    Bhagirath VC; Chan N; Hirsh J; Ginsberg J; de Vries TAC; Eikelboom J
    J Am Coll Cardiol; 2020 Dec; 76(24):2906-2907. PubMed ID: 33303080
    [No Abstract]   [Full Text] [Related]  

  • 14. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
    Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
    Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary stroke prevention with apixaban in nonvalvular atrial fibrillation: A subgroup analysis of the STANDARD study.
    Yasaka M; Umeyama M; Kataoka H; Inoue H
    J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):105034. PubMed ID: 32807446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.
    Milner E; Ainsworth M; Gleaton M; Bookstaver D
    J Clin Pharm Ther; 2022 May; 47(5):668-675. PubMed ID: 35032137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
    Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
    Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care.
    Gulilat M; Tang A; Gryn SE; Leong-Sit P; Skanes AC; Alfonsi JE; Dresser GK; Henderson SL; Rose RV; Lizotte DJ; Teft WA; Schwarz UI; Tirona RG; Kim RB
    Can J Cardiol; 2017 Aug; 33(8):1036-1043. PubMed ID: 28754389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach.
    Lenard A; Hermann SA; Stoll F; Burhenne J; Foerster KI; Mikus G; Meid AD; Haefeli WE; Blank A
    Cardiovasc Drugs Ther; 2024 Aug; 38(4):747-756. PubMed ID: 36870039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment: A Cohort Study in Catalonia.
    Gomez-Lumbreras A; Cortes J; Giner-Soriano M; Quijada-Manuitt MA; Morros R
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):494-501. PubMed ID: 29792125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.